City
Epaper

Mohan Bhagwat, Bhaiyyaji Joshi get Covid jab

By IANS | Published: March 06, 2021 11:53 PM

New Delhi, March 6 Rashtriya Swayamsevak Sangh (RSS) chief Mohan Bhagwat and General Secretary Suresh Bhaiyyaji Joshi took ...

Open in App

New Delhi, March 6 Rashtriya Swayamsevak Sangh (RSS) chief Mohan Bhagwat and General Secretary Suresh Bhaiyyaji Joshi took the first dose of Corona vaccine on Saturday at the National Cancer Institute in Nagpur.

The third phase of Covid vaccination in India started from March 1 in which people over 60 years and those above 45 with comorbidities will get the jab.

Prime Minister Narendra Modi and several Union ministers along with top government officials have received the first dose of vaccine in the third phase.

( With inputs from IANS )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: New DelhiNagpurNational Cancer InstituteMohan BhagwatSuresh Bhaiyyaji JoshiRashtriya Swayamsevak SanghThe new delhi municipal councilMohan bhagawatDelhi south-westSeveral rashtriya swayamsevak sangh
Open in App

Related Stories

NationalNew Delhi: 18-Year-Old Stabbed to Death by Two Individuals Over Romantic Rivalry

MaharashtraNagpur: Student's Quick Thinking Foils Kidnapping Attempt; Two Arrested, Search for Others Underway

MaharashtraSerial Burglar Apprehended in Nagpur: Confesses to Nine Crimes, Police Seize Valuables Worth Rs 3.94 Lakh

MaharashtraDrug Bust in Nagpur: Police Seize MD Powder Worth Rs 3.5 Lakh, Nab Peddlers in Two Operations

MaharashtraNagpur: Tiger Menace Grips Parshivani, Dozens of Animals Killed

Health Realted Stories

HealthFSSAI terms reports of allowing 10x more MRL in herbs, spices 'baseless'

HealthPediatric cancer Patients and their families ‘Second Home’ away from Home

HealthNew Covid variant 'FLiRT' capable of evading the immune system: Experts

HealthSouth Korean govt appears to shelve punitive measures against mass walkout by doctors

HealthCipla, Glenmark recall drugs in US due to manufacturing issues